Yanai Machi, Maeda Akinori, Watanabe Naoko, Sugimoto Naoshi, Matsushita Akiko, Nagai Kenichi, Oida Tatsuo, Takahashi Takayuki
Department of Hematology and Clinical Immunology, Kobe City General Hospital, Kobe, Japan.
Int J Hematol. 2004 Feb;79(2):174-7. doi: 10.1532/ijh97.03053.
Heavy chain diseases (HCD) are monoclonal lymphoproliferative disorders of B-cells characterized by the synthesis of truncated heavy chains without associated light chains. In patients with mu-HCD, which is a very rare form of HCD, neoplastic cells produce immunoglobulin M heavy chain. The prognosis for patients with mu-HCD is poor, and there is no specific treatment for mu-HCD. In this report, we present a patient with mu-HCD accompanied by splenomegaly and thrombocytopenia. We treated this patient with the fludarabine monophosphate therapy we use for patients with B-cell chronic lymphocytic leukemia. After 5 courses of fludarabine monophosphate treatment, the splenomegaly and thrombocytopenia improved. Fludarabine monophosphate therapy may be a new strategy to improve the prognosis of patients with mu-HCD.
重链病(HCD)是B细胞的单克隆淋巴细胞增殖性疾病,其特征是合成无相关轻链的截短重链。在μ-HCD患者中(μ-HCD是HCD的一种非常罕见的形式),肿瘤细胞产生免疫球蛋白M重链。μ-HCD患者的预后较差,且尚无针对μ-HCD的特异性治疗方法。在本报告中,我们介绍了一名伴有脾肿大和血小板减少症的μ-HCD患者。我们用治疗B细胞慢性淋巴细胞白血病患者的单磷酸氟达拉滨疗法对该患者进行治疗。经过5个疗程的单磷酸氟达拉滨治疗后,脾肿大和血小板减少症有所改善。单磷酸氟达拉滨疗法可能是改善μ-HCD患者预后的一种新策略。